Brian Mieczkowski, DO
Pulmonary Disease · Kansas City, MONPI 1114126943
Payments from drug & device makers
Across 180 payments — averaging $41.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$4K
- AstraZeneca$623
- Sanofi$408
- GSK$284
- Boehringer Ingelheim$268
- Regeneron Healthcare Solutions, Inc.$239
- plus $2K from 24 others
What the payments were for
- Travel & lodging$96513%
- Food & beverage$3,45247%
- Education$3,00040%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 5 | $3,982 |
| AstraZeneca | 35 | $623 |
| Sanofi | 17 | $408 |
| GSK | 17 | $284 |
| Boehringer Ingelheim | 13 | $268 |
| Regeneron Healthcare Solutions, Inc. | 9 | $239 |
| Grifols USA, LLC | 10 | $191 |
| Jazz Pharmaceuticals Inc. | 9 | $179 |
| Harmony Biosciences LLC | 7 | $175 |
| Amgen | 5 | $111 |
| Novartis | 6 | $107 |
| Actelion Pharmaceuticals US, Inc. | 4 | $96 |
| Genentech USA, Inc. | 5 | $86 |
| Mylan Specialty L.p. | 4 | $69 |
| Merck | 3 | $60 |
| Inspire Medical Systems, Inc. | 3 | $56 |
| Axsome Therapeutics, Inc. | 2 | $54 |
| Insmed, Inc. | 3 | $54 |
| Azurity Pharmaceuticals, Inc. | 3 | $53 |
| Baxter Healthcare | 3 | $53 |
| Verona Pharma, Inc. | 3 | $51 |
| United Therapeutics Corporation | 2 | $39 |
| Mallinckrodt Hospital Products Inc. | 2 | $35 |
| Shire North American Group Inc | 3 | $34 |
| Pulmonx Corporation | 2 | $31 |
| Astellas Pharma US Inc | 1 | $18 |
| Nabriva Therapeutics, PLC | 1 | $17 |
| Advanced Respiratory, Inc | 1 | $16 |
| Gilead | 1 | $15 |
| Melinta Therapeutics, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ION$3,000
- Da Vinci Surgical System$946
How this compares
$7,417 in reported general payments places this provider in the 65th percentile of 295 pulmonary disease providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XywavSodium,calcium,mag,pot Oxybate | 11 | $176,364 |
| XolairOmalizumab | 27 | $102,259 |
| WakixPitolisant Hcl | 11 | $79,691 |
| NucalaMepolizumab | 14 | $54,798 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 59 | $50,396 |
| Breo ElliptaFluticasone/Vilanterol | 45 | $21,399 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 40 | $19,794 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 31 | $19,705 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 30 | $15,899 |
| SymbicortBudesonide/Formoterol Fumarate | 14 | $4,235 |
| Incruse ElliptaUmeclidinium Bromide | 11 | $3,019 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 77 | $2,397 |
| Arnuity ElliptaFluticasone Furoate | 12 | $2,110 |
| Omeprazole | 42 | $879 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 11 | $763 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKNucala, Trelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $284 | $147,621171 claims |
| Harmony Biosciences LLCWakix | $175 | $79,69111 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $623 | $23,94045 claims |
| Boehringer IngelheimStiolto Respimat | $268 | $19,79440 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 295 pulmonary disease providers in Missouri.
Other pulmonary disease in Kansas City
- Mark YaganKansas City$162K
- Timothy SmithKansas City$107K
- Matthew AboudaraKansas City$30K
- Andrea CoveyKansas City$23K
- Steven HullLees Summit$10.1M
- Thomas SilerSaint Charles$5.5M
- Neil EttingerChesterfield$3.5M
- Humam FarahHannibal$2.7M
- Murali ChakinalaSaint Louis$2.4M
- Joseph OjileSaint Louis$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.